FY2025 EPS Estimates for Tourmaline Bio Increased by Analyst

Tourmaline Bio, Inc. (NASDAQ:TRML) – Investment analysts at Leerink Partnrs boosted their FY2025 earnings estimates for shares of Tourmaline Bio in a report issued on Wednesday, December 11th. Leerink Partnrs analyst T. Smith now forecasts that the company will earn ($3.56) per share for the year, up from their prior estimate of ($4.01). The consensus estimate for Tourmaline Bio’s current full-year earnings is ($3.08) per share. Leerink Partnrs also issued estimates for Tourmaline Bio’s FY2026 earnings at ($4.58) EPS, FY2027 earnings at ($6.32) EPS and FY2028 earnings at ($7.22) EPS.

A number of other equities analysts have also recently issued reports on TRML. Cantor Fitzgerald restated an “overweight” rating and set a $25.00 target price on shares of Tourmaline Bio in a report on Wednesday. Guggenheim reaffirmed a “buy” rating on shares of Tourmaline Bio in a research note on Wednesday. BMO Capital Markets assumed coverage on shares of Tourmaline Bio in a research report on Friday, December 6th. They set an “outperform” rating and a $50.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $49.00 price objective on shares of Tourmaline Bio in a research report on Wednesday. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $54.00.

Tourmaline Bio Stock Down 3.2 %

TRML stock opened at $21.81 on Friday. Tourmaline Bio has a twelve month low of $12.12 and a twelve month high of $48.31. The company has a market cap of $559.21 million, a P/E ratio of -7.73 and a beta of 2.32. The business’s fifty day moving average is $26.02 and its 200-day moving average is $19.82.

Tourmaline Bio (NASDAQ:TRML) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.78) earnings per share for the quarter, beating the consensus estimate of ($0.84) by $0.06.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Blue Owl Capital Holdings LP lifted its position in Tourmaline Bio by 18.5% in the 2nd quarter. Blue Owl Capital Holdings LP now owns 1,715,401 shares of the company’s stock valued at $22,060,000 after acquiring an additional 268,000 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in Tourmaline Bio in the 2nd quarter valued at approximately $909,000. Rhumbline Advisers lifted its stake in Tourmaline Bio by 28,554.3% in the 2nd quarter. Rhumbline Advisers now owns 33,239 shares of the company’s stock valued at $427,000 after acquiring an additional 33,123 shares in the last quarter. Acuta Capital Partners LLC lifted its stake in Tourmaline Bio by 23.2% in the 3rd quarter. Acuta Capital Partners LLC now owns 332,095 shares of the company’s stock valued at $8,538,000 after acquiring an additional 62,481 shares in the last quarter. Finally, California State Teachers Retirement System acquired a new position in Tourmaline Bio during the 1st quarter worth approximately $334,000. Institutional investors and hedge funds own 91.89% of the company’s stock.

About Tourmaline Bio

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.